# Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)

> **NCT03168464** · PHASE1,PHASE2 · TERMINATED · sponsor: **Weill Medical College of Cornell University** · enrollment: 15 (actual)

## Conditions studied

- Non Small Cell Lung Cancer Metastatic

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **RADIATION:** Radiation therapy

## Key facts

- **NCT ID:** NCT03168464
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-09
- **Primary completion:** 2022-03-11
- **Final completion:** 2022-03-11
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2023-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03168464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03168464, "Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03168464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*